Kancera AB

(KNCQF)

By |

Profile

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Contact Information

Website: www.kancera.com
Main Phone: +46 850126080
Address: Karolinska Institutet Science Park
Address 2: Banvaktsvagen 22
City / Town: Solna
Country: SE
Postal Code: 171 48

Issuer Information

Exchange: GREY
Employees: 15
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Contact Information

Website: www.kancera.com
Main Phone: +46 850126080
Address: Karolinska Institutet Science Park
Address 2: Banvaktsvagen 22
City / Town: Solna
Country: SE
Postal Code: 171 48

Issuer Information

Exchange: GREY
Employees: 15
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 0.08 $ 0. (0.00%)
Last Price 0.08 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close 0.08
Last Trade Volume 0 52 Wk Hi N/A 52 Wk Low N/A
Market Cap 37.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 436,404,617.00 EPS (TTM) N/A PE Ratio N/A Exchange Greys